Literature DB >> 3301667

Renal scintigraphic captopril test in the diagnosis of renovascular hypertension.

E Fommei, S Ghione, L Palla, F Mosca, M Ferrari, C Palombo, S Giaconi, P Gazzetti, L Donato.   

Abstract

Angiotensin converting enzyme (ACE) inhibitor-induced renal failure has been reported in bilateral renal artery stenosis and in stenosis in solitary kidneys, but not in unilateral renal artery stenosis. In these patients, however, a functional impairment of the kidney ipsilateral to the stenosis can often be detected after ACE inhibition by scintigraphic techniques employing glomerular radionuclide tracers like 99mTc-diethylenetriamine pentaacetic acid (DTPA). Dynamic renal scintigraphy with 99mTc-DTPA before and 1 hour after administration of captopril, 25 mg (renal scintigraphic captopril test; RSCT), was performed in a selected series of 39 hypertensive subjects with suspected renovascular hypertension. Changes in glomerular filtration rate induced by captopril on the individual kidney were estimated by assessing the early (120-180 seconds) DTPA uptake by the kidney. Values were expressed as the ratio between the kidney with the lower uptake and the contralateral one in 34 patients and as the ratio of the kidney counts to the injected dose in five patients with solitary kidneys, aortic coarctation, or both. Compared with precaptopril values, postcaptopril uptake decreased markedly in 14 subjects (-62.42 +/- 30.94 [SD]%; range, -25 to -100%) and decreased modestly or even increased in the other 25 (+0.57 +/- 9.83%; range, +28 to -13%). Of the 14 subjects considered to be RSCT-positive diagnostic workup revealed either established (10) or strongly suspected (2) renal artery stenosis in 12 and aortic coarctation in 2 subjects. In another patient with established renovascular hypertension, results of the RSCT were negative when performed in the supine position but became positive when repeated in the sitting position.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3301667     DOI: 10.1161/01.hyp.10.2.212

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Screening for renal artery stenosis: useful or not?

Authors:  J K McKenzie
Journal:  CMAJ       Date:  1990-04-15       Impact factor: 8.262

Review 2.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 3.  The diagnosis of renovascular hypertension: the role of captopril renal scintigraphy and related issues.

Authors:  A Prigent
Journal:  Eur J Nucl Med       Date:  1993-07

4.  Inadequacy of captopril challenge test for diagnosing renovascular hypertension in children and adolescents.

Authors:  B Gauthier; H Trachtman; R Frank; G Pillari
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 5.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

6.  Captopril radionuclide test in renovascular hypertension: a European multicentre study. European Multicentre Study Group.

Authors:  E Fommei; S Ghione; A J Hilson; L Mezzasalma; H Y Oei; A Piepsz; D Volterrani
Journal:  Eur J Nucl Med       Date:  1993-07

7.  Technetium-99m diethylene triamine penta-acetic acid and dimercaptosuccinic acid in the detection of a segmental branch stenosis of the renal artery by captopril renography.

Authors:  L Bajnok; J Varga; G Kurta
Journal:  Eur J Nucl Med       Date:  1992

8.  [Status of the captopril test in the diagnosis of hypertension].

Authors:  S Degenhardt; H Friedrich; G Wambach; J H Fischer; W Gross-Fengels; A Linden; K F Neufang; W Hummerich
Journal:  Klin Wochenschr       Date:  1989-11-03

9.  Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension.

Authors:  Jingsi Zhang; Mingyu Wang; Kehui Sun; Yanchun Ding
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.